NMN vs NR: Comparing NAD+ Precursors in the Literature

In plain English

This page compares the two most common NAD+ precursors — NMN and NR (both building blocks the body turns into NAD+, the cell's energy-handling helper molecule). The question NAD+ vs NMN really asks is which building block to feed the system, since the bare coenzyme is poorly absorbed. The short answer from the trials: both NMN and NR reliably raise the NAD+ measured in blood, by a roughly similar amount in a recent head-to-head. They take slightly different doors into the cell. Below, the two are read side by side — uptake, dose-response, and delivery claims — each cited.

Two precursors, two doors into the cell

NMN and NR are the two principal NAD+ biosynthetic intermediates, and they reach the coenzyme by overlapping but distinct routes ^[9]. NR (nicotinamide riboside) is phosphorylated to NMN by the NRK kinases (NRK1/NRK2) and then converted onward to NAD+ — a route independent of the Preiss-Handler pathway ^[9]. NMN, by contrast, can be absorbed directly through the dedicated Slc12a8 transporter in the gut and raise NAD+ in peripheral tissues within minutes in mice ^[9].

The routes carry trade-offs. NR is unstable in murine plasma, degrading to nicotinamide, while NMN's direct transporter gives it a faster tissue read in animal models ^[9]. Both intermediates show larger responses in aged animals than young, consistent with correcting an age-related NAD+ deficit ^[9]. For human readers, though, the dose-response figures below matter more than the murine kinetics — and there the two are closer than the mechanism suggests.

Nicotinamide riboside (NR): the most clinically studied precursor

Nicotinamide riboside is the precursor with the cleanest controlled dose-response in humans. In healthy overweight adults, NR at 100, 300, and 1000 mg/day for eight weeks raised whole-blood NAD+ by 22%, 51%, and 142% respectively, with the elevation maintained throughout the study ^[4]. Critically for tolerability, NR produced no flushing — distinguishing it from high-dose niacin — and did not elevate LDL cholesterol or disrupt one-carbon metabolism, with no significant adverse-event difference from placebo at any dose ^[4].

NR also carries the field's reassuring safety ceiling. The 2023 review of NAD+-boosting trials noted NR tested up to 2,000 mg/day for 20 weeks with no serious adverse events, alongside NMN tested up to 24 weeks ^[8]. As with NMN, the consistent finding is the blood-NAD+ rise; the functional endpoints across NR trials were the more inconsistent part of the record ^[8].

Head to head: how NMN and NR compare

Direct comparison is now possible. A 2026 study set three NAD+ boosters against each other and found NR and NMN comparably raised circulatory NAD+ by roughly two-fold, while nicotinamide (NAM) was ineffective ^[15]. That is the cleanest head-to-head answer to NAD+ vs NMN and NR: the two leading precursors are broadly equivalent on the blood-NAD+ endpoint, and both outperform plain nicotinamide.

The same study added a twist that complicates any simple ranking: ex vivo fermentation confirmed that gut microbes convert NR and NMN to nicotinic acid, implicating the gut microbiome as a variable in how strongly any individual responds to oral precursors ^[15]. Individual response, in other words, may depend partly on a reader's microbiome — a frontier the current trials are only beginning to map.

Liposomal, sublingual and transdermal NAD+ delivery claims

Beyond capsules and powders, the market sells liposomal NAD+, sublingual lozenges, intranasal sprays, and transdermal patches — and the controlled evidence for these formats is thin. The bulk of human data comes from oral precursor capsules and powders of NMN and NR ^[4][8]; alternative delivery routes have little controlled evidence behind their absorption claims. Liposomal and transdermal NAD+ in particular face the same fundamental obstacle as any plain-NAD+ product: the intact coenzyme is large and charged, and getting it across a membrane in a usable form is exactly the problem the precursors sidestep. Until controlled trials test these formats directly, the claims outrun the data.

Is taking NAD orally effective?

Plain oral NAD+ is poorly absorbed intact, so swallowing the coenzyme itself is the least effective approach ^[9]. The precursors NMN and NR are the rational oral route, and both reliably raise blood NAD+ in randomized trials ^[3][4]. Hard clinical benefit beyond the blood-NAD+ rise remains preliminary, but on the absorption question, precursors are what works orally.

Do NAD patches work?

Transdermal NAD+ patches, like sublingual and intranasal formats, are marketed but have little controlled evidence behind them ^[8]. The human trial record runs almost entirely on oral precursor capsules and powders ^[4]. No cited study establishes that a NAD+ patch raises blood NAD+ the way oral NMN or NR do.